Previous Client

Return to Sector or view our Current Clients.

Untitled Document

X-Change Corp. (XCHC)

X-Change Corp. (XCHC) specializes in cannabinoid based extracts and products that target medical cannabis, nutraceutical, cosmeceutical, and social usage solutions through multiple Phytiva brand product lines, products, and services. The company plans to launch a combination of retail and wholesale products, medical cannabis dispensaries, cannabis research in clinics and laboratories, and other legal state and foreign operations.

The company’s Phytiva brand utilizes the unique and potent benefits of cannabinoids, the natural components found in the cannabis sativa L. plant, from which cannabis and hemp are produced. The company’s formulations target not just the symptom, but the cause of critical ailments. Because the body responds extremely well to their properties, X-Change believes cannabinoids provide the ideal solution for better treatment and patient outcomes.

Respect for human life is a core value of the Phytiva brand, and X-Change believes that there are countless possibilities to be unleashed from the cornucopia of nature for good health and wellbeing. Phytiva uses the latest science and technology to study these possibilities with a key focus on making its carefully developed solutions accessible to all. First, all of Europe, the United States, and then beyond.

The staggering numbers of cases of HIV/AIDS, cancer, autoimmune disease, MRSA, diabetes, and a number of other ailments is X-Change’s motivation to bring superior products to their respective markets, but the company is also targeting opportunities in the $350 billion personal care market. Leveraging its unique formulations and the branding abilities of its team, X-Change is well positioned to provide cannabinoid-based solutions to the mainstream market through multiple avenues.

Transfer Agent
Signature Stock Transfer, Inc.
2632 Coachlight Ct.
Plano, TX 75093

Investor Relations
3370 N. Hayden Rd.
Scottsdale, AZ. 85251

Key Investment Highlights
Sales Forecast to Rise +$50 Million in 3-5 Years
Will Benefit from Shifts in Cannabis Legalization
Product Line Addresses Critical Demand

Sector: Healthcare
Industry: Drugs
Sub-industry: Specialized Medicine

Share Information


Additional Resources


The QualityStocks

Read the articles covering the biggest movers in the markets today.



Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks markets.


The QualityStocks Daily

Go back to see our previous newsletters and find out what you might have missed.